TwoStep Therapeutics is pioneering a multi-targeting platform to advance a pipeline of targeted therapies that are broadly applicable across solid tumors. With this approach, the company aims to transform cancer treatment by extending precision medicines to more diverse tumor types and patient populations, for which few options exist. TwoStep Therapeutics was co-founded by CEO, Caitlyn Miller, in collaboration with world-renowned academic entrepreneurs at Stanford University: Jennifer Cochran, Ronald Levy, and Nobel Laureate Carolyn Bertozzi. For more information, visit www.twosteptx.com.  

TwoStep Therapeutics

Our co-founder and CEO Caitlyn Miller, PhD spoke with Kyle LaHucik at Endpoints News about our work developing a novel tumor-targeting platform for solid tumors - and how the broad applicability of this approach opens up new possibilities for cancer treatment.

Read more in Endpoints News👇 
https://lnkd.in/gx_4paV3

We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors.

Our delivery platform is built around a unique tumor-targeting agent that can selectively bind five targets that are highly expressed on solid tumors. This multi-targeting feature enables broad applicability across a wide range of tumor types and patient populations, overcoming the limitations of traditional single-antigen targeting approaches. 

Led by co-founder and CEO Caitlyn Miller, PhD, our mission is to revolutionize cancer care by developing precise, effective, and broadly applicable targeted therapies.

Our work is guided by world-class academic-entrepreneurs at Stanford, including co-founders Carolyn Bertozzi, Jennifer Cochran and Ron Levy.

We launched from the Stanford University Innovative Medicines Accelerator (IMA) and are backed by a syndicate of high quality investors, led by NFX with participation from 2048 Ventures, Alexandria Real Estate Equities, Inc., Cooley LLP’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. 

Read the full press release to learn more: 
Press Release: https://lnkd.in/gErBpaBg
Endpoints article: https://lnkd.in/gx_4paV3
Company website: www.twosteptx.com

Phage display-derived peptides used as therapeutic alternatives to antibodies, potentially competing with TwoStep Therapeutics' integrin-binding peptides.

Phage Display-Derived Peptides

ATN-161, an integrin binding peptide, is being investigated as a novel therapy for cancer, potentially competing with TwoStep Therapeutics' technology.

ATN-161

Engineered knottin peptides designed as a new class of agents for inhibiting tumor angiogenesis by binding to specific integrin receptors, posing as potential competitors to TwoStep Therapeutics' integrin-binding peptides.

Engineered Knottin Peptides

TwoStep Therapeutics is a biotechnology company specializing in tumor-targeting therapies. It utilizes a proprietary Polyspecific Integrin-binding Peptide (PIP) technology to deliver therapeutic payloads specifically to solid tumors, aiming to enhance the efficacy and safety of cancer treatments.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 1, 2024 8:43 AM	5f0e72d7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 1, 2024 9:21 AM	8f4e6e21
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	386a0fb2
crunchbase profile	general
li profile	general	Jul 1, 2024 8:43 AM	e25cda26
translate crunchbase fundingrounds	general
peers	general
news basic	general	Jul 1, 2024 8:43 AM	e82f42e2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:TWOSTEPTX

TwoStep Therapeutics